Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: Combination therapy of Tablet Norfloxacin and Tablet Rifaximin: Combination therapy of Tablet Norfloxacin 400 mg once daily
+ Tablet Rifaximin 550 mg twice daily
Control Intervention1:
Sponsors
Pt BD Sharma PGIMS Rohtak
Eligibility
Inclusion criteria
Inclusion criteria: All patients with cirrhosis and ascites with hepatic encephalopathy with either gastrointestinal bleed, shock (systolic blood pressure <90 mmHg), fever or other signs of systemic inflammation like pain abdomen, diarrhea as well as in patients with worsening liver or renal function and hepatic encephalopathy shall be screened for spontaneous bacterial peritonitis by diagnostic paracentesis
Exclusion criteria
Exclusion criteria: 1. Age 70 years 2. Pregnant females 3. Patients with chronic respiratory or kidney disease 4. Patients with diabetes mellitus or hypertension 5. Patients with hepatocellular carcinoma 6. Patients with abnormal ECG or chest radiograph
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrent episodes of spontaneous bacterial peritonitis and/or hepatic encephalopathy till next 3 months 28 day and 90 day mortalityTimepoint: Recurrent episodes of spontaneous bacterial peritonitis and/or hepatic encephalopathy till next 3 months 28 day and 90 day mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of hospitalisation over next 3 months Episodes of upper GI bleed, acute kidney injury over next 3 months Change in model for end stage liver disease and Child Turcotte Pugh score over next 3 monthsTimepoint: Number of hospitalisation over next 3 months Episodes of upper GI bleed, acute kidney injury over next 3 months Change in model for end stage liver disease and Child Turcotte Pugh score over next 3 months | — |
Countries
India
Contacts
Public ContactDr Vaibhav
Pt BD Sharma Post Graduate Institute of Medical Sciences
Outcome results
None listed